Fig 1.
PRISMA flow diagram of study selection.
Fig 2.
Overview of study characteristics.
Table 1.
Cost-effectiveness finding of KRAS testing for corresponding targeted therapies.
Table 2.
Cost-effectiveness finding of RAS testing for corresponding targeted therapies.
Table 3.
Cost-effectiveness of UGT1A1 testing.
Table 4.
Cost-effectiveness of targeted therapies licensed with companion biomarkers.